Figure 3. CC-115 blocks DNA-PKcs and mTOR activation in RCC cells. 786-O RCC cells, the primary human RCC cells (“RCC1/2”), or the primary human renal epithelial cells (“Pri-Epi”), were treated with CC-115 (“CC”, 5 μM) for 2h, DNA-PKcs activity (A) and expression of listed proteins in total cell lysates (B, C-”Inputs”, D, E) were shown. mTOR-Sin1-DNA-PKcs association was tested by co-immunoprecipitation assay (C, “IP”). Expression of the listed proteins in control 786-O cells (“C”) and DNA-PKcs- and mTOR-double knockout (DKO) 786-O cells were shown (F), cells were also treated with/without CC-115 (5 μM) for 48/72h, cell viability and proliferation were tested by CCK-8 assay (G) and BrdU ELISA assay (H), respectively. The exact same number of “C” and DKO cells were plated initially (“0h”) for the functional assays (G, H). *P < 0.05 vs. untreated control group (“Ctrl”) (A). *P < 0.05 vs. “C” cells (G, H).